FY2026 Earnings Forecast for Accuray Issued By Roth Capital

Accuray Incorporated (NASDAQ:ARAY) – Equities research analysts at Roth Capital boosted their FY2026 EPS estimates for shares of Accuray in a research report issued to clients and investors on Tuesday, November 19th. Roth Capital analyst J. Wittes now expects that the medical equipment provider will post earnings of $0.11 per share for the year, up from their prior estimate of $0.08. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share.

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Accuray Trading Up 2.1 %

Shares of Accuray stock opened at $1.93 on Friday. The company’s 50-day moving average price is $1.85 and its 200-day moving average price is $1.83. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. Accuray has a 12-month low of $1.40 and a 12-month high of $3.05. The company has a market cap of $194.10 million, a price-to-earnings ratio of -11.21 and a beta of 1.40.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. The company had revenue of $101.55 million for the quarter, compared to analyst estimates of $98.10 million. During the same period in the previous year, the company posted ($0.03) EPS.

Institutional Trading of Accuray

Large investors have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its stake in Accuray by 253,483.3% in the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 15,209 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Accuray during the 2nd quarter valued at $30,000. US Bancorp DE lifted its holdings in shares of Accuray by 1,087.7% during the 3rd quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 16,316 shares during the last quarter. Caprock Group LLC purchased a new position in Accuray in the third quarter worth $36,000. Finally, Intech Investment Management LLC bought a new position in Accuray in the third quarter valued at $41,000. Institutional investors own 64.08% of the company’s stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.